
Opinion|Videos|October 7, 2024
COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please discuss the updated data from the COMMANDS study presented at ASCO 2024.
- What is the importance of the outcome data for luspatercept vs epoetin alfa in 1L treatment? (
Zeidan et al, J Clin Oncol. 2024; 42(suppl 16): 6565 ); (Della Porta et al, Lancet Haematol. 2024; 11:e646-658 .)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















